Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−9.26 USD
−55.36 M USD
530.00 K USD
4.59 M
About Orgenesis, Inc.
Sector
Industry
CEO
Vered Caplan
Website
Headquarters
Germantown
Founded
2008
FIGI
BBG000PPQ0W2
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ORGS is 1.21 USD — it has increased by 10.00% in the past 24 hours. Watch Orgenesis, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Orgenesis, Inc. stocks are traded under the ticker ORGS.
ORGS stock has risen by 10.25% compared to the previous week, the month change is a 5.22% rise, over the last year Orgenesis, Inc. has showed a −97.60% decrease.
ORGS reached its all-time high on Mar 20, 2012 with the price of 23,904.00 USD, and its all-time low was 0.87 USD and was reached on Nov 15, 2024. View more price dynamics on ORGS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ORGS stock is 14.55% volatile and has beta coefficient of 1.47. Track Orgenesis, Inc. stock price on the chart and check out the list of the most volatile stocks — is Orgenesis, Inc. there?
Yes, you can track Orgenesis, Inc. financials in yearly and quarterly reports right on TradingView.
Orgenesis, Inc. is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
ORGS earnings for the last quarter are −1.93 USD per share, whereas the estimation was 1.70 USD resulting in a −213.53% surprise. The estimated earnings for the next quarter are 2.50 USD per share. See more details about Orgenesis, Inc. earnings.
Orgenesis, Inc. revenue for the last quarter amounts to 347.00 K USD, despite the estimated figure of 18.50 M USD. In the next quarter, revenue is expected to reach 24.20 M USD.
ORGS net income for the last quarter is −9.12 M USD, while the quarter before that showed −8.90 M USD of net income which accounts for −2.43% change. Track more Orgenesis, Inc. financial stats to get the full picture.
No, ORGS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 146.00 employees. See our rating of the largest employees — is Orgenesis, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Orgenesis, Inc. EBITDA is −24.05 M USD, and current EBITDA margin is −10.06 K%. See more stats in Orgenesis, Inc. financial statements.
Like other stocks, ORGS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Orgenesis, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Orgenesis, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Orgenesis, Inc. stock shows the sell signal. See more of Orgenesis, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.